MedTrace Logo

A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia

NCT07016269 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 358

Last updated 2025-10-02

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 500 mg administration in patients with biliary dyspepsia

Conditions

  • Biliary Dyspepsia

Interventions

DRUG

CnU capsule 500 mg(250mg 2 capsule)

According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.

DRUG

CnU placebo capsule 500 mg(250mg 2 capsule)

According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.

Sponsors & Collaborators

  • Myungmoon Pharma. Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-29
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07016269 on ClinicalTrials.gov